The world is in the midst of a diabetes epidemic; an estimated 415 million people have been diagnosed with diabetes. That number is expected to grow to 642 million by 2040. According to a study released by the International Diabetes Federation (IDF) in December 2015, 11 percent of U.S. adults – about 30 million – have diabetes.

The challenge is profound; the disease puts people at risk of numerous complications, including diabetic retinopathy, the leading cause of blindness in working age adults. Nearly one-third of adults with diabetes will develop diabetic retinopathy, a huge cost to personal welfare and to global economics. In 2014, the economic impact diabetic retinopathy in the United States alone was $4.3 billion annually, and is projected to increase to $6.9 billion by 2025.

Who bears the cost? Individuals and their families, governments, private insurers, and ultimately society at large all suffer. Fortunately, the earlier diabetic retinopathy is diagnosed, the sooner it can be treated and managed. It’s a global challenge VisionQuest i-Rx is committed to solving.